Trial Profile
A Dose-Block Randomized, Placebo controlled (Double-blind), Active Controlled(Open-label), Dose-escalation Study to investigate the tolerability, and Pharmacokinetics/Pharmacodynamics of HL2351 after a Single Subcutaneous Administration in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2019
Price :
$35
*
At a glance
- Drugs HL 2351 (Primary) ; Anakinra
- Indications Rheumatoid arthritis
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Handok Inc
- 28 Oct 2019 Results published in the British Journal of Clinical Pharmacology
- 05 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Jul 2014 New trial record